Can intralesional immunotherapy change how we manage oral epithelial dysplasia? An early clinical trial of nivolumab reports encouraging results in lesion reduction and histological improvement. We examine the findings, safety considerations, and the critical question: can these responses actually reduce the risk of oral cancer?
